Relationship Between Antidepressant Medication Treatment and Suicide in Adolescents

Mark Olfson, MD, MPH; David Shaffer, MD; Steven C. Marcus, PhD; Ted Greenberg, MPH

Context: A decade of increasing antidepressant medication treatment for adolescents and corresponding declines in suicide rates raise the possibility that antidepressants have helped prevent youth suicide.

Objective: To evaluate the relationship between regional changes in antidepressant medication treatment and suicide in adolescents from 1990 to 2000.


Participants: Youth aged 10 to 19 years who filled a prescription for antidepressant medication and same-aged completed suicides from 588 three-digit ZIP code regions in the United States.

Main Outcome Measures: The relationship between regional change in antidepressant medication treatment and suicide rate stratified by sex, age group, regional median income, and regional racial composition.

Results: There was a significant adjusted negative relationship between regional change in antidepressant medication treatment and suicide during the study period. A 1% increase in adolescent use of antidepressants was associated with a decrease of 0.23 suicide per 100000 adolescents per year (β = −0.023, t = −5.14, P < .001). In stratified adjusted analyses, significant inverse relationships were present among males (β = −0.032, t = −3.81, P < .001), youth aged 15 to 19 years (β = −0.029, t = −3.43, P < .001), and regions with lower family median incomes (β = −0.023, t = −3.73, P < .001).

Conclusions: An inverse relationship between regional change in use of antidepressants and suicide raises the possibility of a role for using antidepressant treatment in youth suicide prevention efforts, especially for males, older adolescents, and adolescents who reside in lower-income regions.

Arch Gen Psychiatry. 2003;60:978-982
medication treatment and suicide by adolescents in a large number of US geographic regions.

### METHODS

Four sources of data were used to examine regional variation in trends in the relationship between antidepressant medication treatment and suicide rates: (1) prescription data from a large pharmacy benefit management organization, (2) national suicide mortality files from the Centers for Disease Control and Prevention, (3) regional geographic characteristics from the US Census Bureau, and (4) information on the geographic distribution of physicians from the Area Resource File.

#### ANTIDEPRESSANT RATES

Rates of antidepressant medication treatment for each 3-digit ZIP code region were calculated from data provided by AdvancePCS, Irving, Tex, the nation’s largest pharmacy benefit service organization. AdvancePCS provided complete pharmacy data for approximately 340,000 adolescents for a 1-month period in 1989 and approximately 720,000 adolescents for a corresponding 1-month period in 2001. The datasets include the national drug code, patient age, patient sex, encrypted identification number, and the 3-digit ZIP code of the filling pharmacy for each prescription. Mail-order prescriptions were excluded from the analysis, because the filling “pharmacy” was unlikely to be within the geographic region of the patient.

Person-level antidepressant rates per 1000 patients receiving medication were calculated, stratified by sex and 2 age groups: 10 to 14 years and 15 to 19 years. A count of adolescents receiving medication in each group served as the denominator for antidepressant medication treatment rates. The mean number of adolescents receiving medication per region was 518 (1989) and 1086 (2000), and the median was 322 (1989) and 713 (2000).

#### SUICIDE RATES

Rates of suicide were calculated from the Centers for Disease Control and Prevention’s Compressed Mortality Files. These data provide underlying cause of death (4-digit International Classification of Diseases, Ninth Revision code) for all deaths occurring in the United States stratified by county of residence, sex, and age group, and population estimates from the US Census Bureau. Data were pooled to provide stable estimates of mortality (independent variable) and suicide (dependent variable) accounting for regional racial composition, median income, and physicians per capita for each year and change over time, as appropriate. Similar analyses are presented stratified by sex, age group, median regional income, and racial composition. Two-tailed, unpaired t tests were used for comparison. The Cook’s D statistic was used to remove extreme outliers (D>0.4) from the regression analyses. No more than 1 ZIP code region was removed from any model. Separate models examined suicide by firearms and by all other causes of suicide.

A further post hoc analysis examined change in tricyclic antidepressant medication treatment in relation to suicide.

#### ANTIDEPRESSANT MEDICATION TREATMENT AND SUICIDE

In 1990 and in 2000, there was a significant positive relationship between regional antidepressant medication treatment and suicide, indicating that regions with high rates of antidepressant medication treatment also tend to have high suicide rates. Significant associations were observed for most sex, age, race, and income strata (Table).

#### TIME TRENDS

A significant negative relationship was observed between 1990 and 2000 for changes in the regional rates of overall antidepressant medication treatment and changes in the regional suicide rates after adjusting for change in percentage white population, median income, and number of physicians per capita (Table). A significant negative adjusted trend association was observed in stratified analyses of male children; children aged 15 to 19 years; and in lower-income regions. The strength of the relationship between change in use of antidepressants and change in suicide rate was similar in nonfirearms (β = −0.012, t = 3.56, P < .001) and nonfirearms (β = −0.010, t = 4.38, P < .001) suicide.

The rate of adolescents filling prescriptions for tricyclic antidepressant medications was low in 1990 (1.2%) and 2000 (0.8%). In a post hoc analysis limited to regions with 1 or more antidepressant prescription, change in all types of antidepressant prescriptions was negatively related to change in suicide rate (β = −0.016, t = 3.19,
P = .002), but change in the rate of tricyclic antidepressant medication treatment was not related to the change in suicide rate (β = −.010, t = .53, P = .60).

In cross-sectional analyses, increased regional antidepressant medication treatment is linked to higher suicide rates. Although this relationship may reflect antidepressant-triggered suicide, clinical and forensic studies cast doubt on this interpretation. Communities with high rates of suicide (and presumably high rates of severe psychiatric illnesses) may simply tend to use more antidepressant medications than communities with low rates of suicide.

In accord with most studies of European countries, an increase in antidepressant medication treatment was inversely related to the rate of suicide. In our study, a 1% increase in adolescent use of antidepressants was associated with a decrease of 0.23 suicide per 100,000 adolescents per year. This inverse time trend was not observed for tricyclic antidepressants. In contrast to the positive findings from clinical trials of treating adolescent depression with selective serotonin reuptake inhibitors, the findings with tricyclic antidepressants have been disappointing. Compared with tricyclic antidepressants, selective serotonin reuptake inhibitors are associated with greater medication adherence and are less dangerous when taken in overdose.

A relationship between antidepressant medication treatment and suicide is exceedingly difficult to study with clinical experimental methods. Pooled analyses of depressed adult patients from clinical trials reveal statistically similar rates of suicide in participants receiving placebo and antidepressants. Although such findings raise uncertainty regarding whether antidepressant medications can reduce suicide risk, the exclusion of individuals with a serious risk of suicide, short follow-up periods, high subject attrition, and the small number of suicides in clinical trials complicate interpretation of these findings.

In the current study, significant inverse trends in antidepressant medication treatment and suicide rates were evident for older adolescents and males but not younger adolescents and females. Compared with younger adolescents who commit suicide, older adolescents who commit suicide are more likely to have a diagnosable disorder, including depression, and so these patients may be more likely to benefit from antidepressants. Previous research also indicates that compared with females, males are at lower risk of suicide attempts but at much greater risk of suicide. With the availability of more effective antidepressant treatments for young people, gender differences in the case fatality rate may have created more clinical opportunities to lower the risk of suicide in males than females. In this regard, it may be worth exploring whether selective serotonin reuptake inhibitor–mediated suppression of impulsive aggressive behavior reduces suicidal behavior in high-risk males.

An inverse time trend was evident for adolescents residing in lower-income regions but not higher-income regions. Lower-income communities may have higher base rates of psychiatric disorder and a greater unmet need for mental health services. Increasing mental health treatment in these communities may selectively reach a proportionately larger number of youth at high risk for suicide.
ships between rates of antidepressant medication treatment and suicide rates. Regional variation in the proportion of the population in the pharmacy database may introduce further measurement error. However, the pharmacy database is quite large, covering 75 million members in 2000. An absence of diagnostic data prevents analysis by clinical indication of the antidepressant medications. Further research is also needed to determine whether the findings are specific to antidepressants or whether similar correlations exist for other psychotropic medications or their interaction with antidepressants. Most important, the findings are open to ecologic challenge because they relate regional rather than individual characteristics.

The relationship between suicide and mental status is not simple, and merely expanding access to antidepressant medications is unlikely to ensure the abolition or even a continued rapid decline in adolescent suicide rates. Nevertheless, the current findings are consistent with suicide risk reduction policies that seek to improve the identification and psychopharmacological treatment of young people with major depression and other antidepressant-responsive psychiatric disorders.

Submitted for publication May 15, 2003; final revision received July 25, 2003; accepted August 5, 2003.

Dr Olfson serves on an advisory board and is a principal investigator for a research grant from Bristol-Myers Squibb; is a consultant on a research project sponsored by Wyeth Pharmaceuticals; and is a co-investigator on research projects sponsored by Eli Lilly & Company and GlaxoSmithKline. Dr Marcus is a consultant on a research project sponsored by Wyeth Pharmaceuticals.

We thank Duane McKinley, BA, and Heather Haupert, MS, of AdvancePCS for providing technical assistance.

Corresponding author: Mark Olfson, MD, Department of Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, 1051 Riverside Dr, New York, NY 10032 (e-mail: olfsonm@child.cpmc.columbia.edu).

REFERENCES

41. Quitkin FM. What conditions are necessary to assist antidepressant efficacy? Arch Gen Psychiatry. 2000;57:323-324.

Correction

Error in Reference. In the letter titled “Standardized Mortality Ratio in Bulimia Nervosa,” in the August issue of the ARCHIVES (2003;60:851), Keel et al, listed as reference 9, should have been listed as the first reference instead of Halmi et al.